Autism is one of the most common developmental disabilities that afflict individuals of all ethnic and socioeconomic backgrounds. In 2020, the CDC reported that in the U.S. approximately 1 in 54 children are diagnosed with autism.
A new study highlights that Bryostatin may help normalize autistic spectrum disorders by regenerating synapses in other degenerative brain conditions that lead to autism.
Synaptogenix, Inc. formerly Neurotrope Bioscience, Inc., announced a new report in collaboration with the Fragile X Foundation and UK scientists published by “Scientific Reports,” an online peer-reviewed open access scientific journal through Nature.com, titled “Chronic Bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice.”
Fragile X syndrome is a rare genetic condition affecting the X-chromosome that causes intellectual disability and cognitive impairment. There are fewer than 200,000 Fragile X syndrome cases per year in the US.
Synaptogenix, Inc is a clinical-stage biopharmaceutical company that has Bryostatin-1 approved as an Orphan Drug status for Fragile X syndrome by the U.S. Food and Drug Administration. Bryostatin-1 has already undergone testing in a large safety data base of more than 1,500 people in cancer studies that will further inform clinical trial designs.
While this study is still in the early stages, Bryostatin has already shown regenerative potential during the past two decades in pre-clinical models of Alzheimer’s disease (AD), stroke, Traumatic Brain Injury, Parkinson’s disease, and Multiple Sclerosis. Synaptogenix plans to explore how Bryostatin may treat autism, and move forward on their current Phase 2 studies with Alzheimer’s disease patients